Basics |
Corbus Pharmaceuticals Holdings, Inc. Common Stock
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
|
IPO Date: |
November 1, 2014 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$78.93M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.31 | 3.91%
|
Avg Daily Range (30 D): |
$0.32 | 4.87%
|
Avg Daily Range (90 D): |
$0.34 | 4.25%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.31M |
Avg Daily Volume (30 D): |
.13M |
Avg Daily Volume (90 D): |
.18M |
Trade Size |
Avg Trade Size (Sh.): |
263 |
Avg Trade Size (Sh.) (30 D): |
64 |
Avg Trade Size (Sh.) (90 D): |
68 |
Institutional Trades |
Total Inst.Trades: |
430 |
Avg Inst. Trade: |
$1.77M |
Avg Inst. Trade (30 D): |
$.78M |
Avg Inst. Trade (90 D): |
$.95M |
Avg Inst. Trade Volume: |
.03M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$2.05M |
Avg Closing Trade (30 D): |
$.78M |
Avg Closing Trade (90 D): |
$.78M |
Avg Closing Volume: |
39.83K |
|
|
|
|
Financials |
|
TTM |
Q4 2024 |
FY 2024 |
Basic EPS
|
$-1.39
|
$-.76
|
$-3.68
|
Diluted EPS
|
$-1.39
|
$-.76
|
$-3.68
|
Revenue
|
$ 1.68M
|
$ 3.55M
|
$ 6.31M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -16.98M
|
$ -9.53M
|
$ -40.21M
|
Operating Income / Loss
|
$ -19.78M
|
$ -12.61M
|
$ -48.72M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ M
|
$ -2.23M
|
$ 3.47M
|
PE Ratio
|
|
|
|
Splits |
Feb 14, 2023:
30:1
|
|